1. **2013 SCHOOL CHOICE FAIR**

The School Choice fair date is in conflict with the high profile Super Bowl. Because of this, we will be establishing a different date. When the date has been selected, we will advertise it.

Tamyra Kelly, ext. 1050

2. **TECHNOLOGY UPDATE**

i-Parent - The technology department has pushed out an iTunes U course for parents called i-Parent. The course will communicate with parents every aspect of the Blended Learning Initiative. Examples of materials already posted in i-Parent are the iPad Deployment Night video, the Student Technology Handbook, links to useful websites such as the EACS LiveBinder, and the First 14 Days video tutorials. This course can be viewed utilizing the student iPad. The technology department will continue to add material throughout the year.

Bill Diehl, ext. 3143

3. **2012-13 COLLABORATION DAY**

The first Collaboration Day of the 2012-13 school year will be on Wednesday, September 5. We will NOT be doing the iPad training "The First 14 days of School" on this day. This will shift the schedule back one day so "The First 14 Days" will finish on Monday, September 10. Thank you for your patience and understanding.

Chris Hissong, ext. 1002

4. **2013 LILLY TEACHER CREATIVITY AWARD APPLICATION**

If you are a licensed teacher, principal, assistant principal, library / media specialist or guidance counselor, you are eligible to apply for one of 100 awards for $10,000 that Lilly will be giving away to educators in Indiana through the Lilly Teacher Creativity Award program. Teacher Creativity Awards provide funding to help refresh and renew the educators who are selected by Lilly's review committee. Application details are available at the following Lilly Endowment website: [http://www.teachercreativity.org/](http://www.teachercreativity.org/). The application deadline is **11/02/12**. If you are interested or think you might be interested in completing an application, please review the materials available at Lilly Endowment's website and refer to **Enclosure #1** describing the awards. **Contact Rose Fritzinger by October 1st** and she will help you draft an application. EACS has indeed been fortunate to have a number of Lilly Teacher Creativity Award winners over the past several years and we very much appreciate the Lilly Endowment's provision of these incredible Awards.

Rose Fritzinger, ext. 3161
5. **URBAN RUN WALK**

See Enclosure #2 regarding the upcoming Urban Run/Walk on September 15, 2012.

Tamyra Kelly, ext. 1050

6. **ROSE-HULMAN’S HOMEWORK HOTLINE**

Rose-Hulman's Homework Hotline provides FREE math and science homework help to Indiana students in grades 6-12. Students may contact the Homework Hotline from 7 p.m. to 10 p.m. (Eastern Daylight Time), September through May toll-free at 1-877-ASK-ROSE or online at www.AskRose.org.

Tamyra Kelly, ext. 1050

7. **CONSTITUTION DAY**

Would you like an Indiana Supreme Court Justice to visit your classroom? In celebration of Constitution Day 2012, Chief Justice Brent Dickson and Associate Justices Steven David and Mark Massa will visit three Indiana classrooms. To be considered for one of the visits, all you have to do is write a short email explaining why you would like a justice to visit your classroom and what type of activity you would like the justice to participate in with your class. The contest is open to educators from across the state teaching grades 4-12. For more information, visit the [Constitution Day 2012 webpage](http://www.in.gov/library/statehood.htm).

Tamyra Kelly, ext. 1050

8. **WHAT INDIANA MEANS TO ME**

The Indiana Statehouse Tour Office in conjunction with the Indiana State Library is coordinating an essay competition to commemorate “Indiana Statehood Day”. Winners will be honored at the Statehood Day Celebration taking place at the Indiana Statehouse on Tuesday, December 11, 2012. For additional information regarding events planned for Statehood Day, please visit [http://www.in.gov/library/statehood.htm](http://www.in.gov/library/statehood.htm).

Tamyra Kelly, ext. 1050

9. **LICENSE RENEWAL**

The LVIS - License Verification System - requires teachers to attach their documentation when submitting requests for teacher license renewal. If the documentation is not attached the renewal will be denied. The documentation should be in the form of PGP certificates, official transcripts from universities for courses completed or letters from principals documenting committee work completed outside of regular work hours. Providing all documentation will speed up the license renewal process.

Chris Hissing, ext. 1002
10. **HIGH SCHOOL CREDIT RECOVERY**

There will be a meeting on Thursday, September 6 from 3:30 to 4:30 at Park Hill in the Staff Development Room to discuss Compass Odyssey. Please bring any questions or suggestions that you may have to the meeting. We will also be reviewing the weighting of grades for the Compass courses. Teachers that should attend are those currently running the learning labs at the school, summer school teachers, alternative school teachers and any other teachers that are interested in utilizing this program. PGP’s will be awarded for attending this voluntary meeting.

Chris Hissong, ext. 1002

11. **INTERNET PROBLEMS**

If you are experiencing problems using Internet Explorer 8, you can download an alternate browser such as Firefox, Google Chrome etc. To verify the version of Internet Explorer, open Internet Explorer, click on Help - About.

If you have any questions, please contact the Help Desk, X4357.

Bill Diehl, ext. 3125

12. **RX ANNOUNCEMENTS**

Enclosures #3 are four Rx announcements/additional information for all employees that participate in our Group Health Insurance Plan. If you have questions please contact Leslie Reisgies at ext.1051.

Peggy Rohrbacher, ext. 1009

13. **GUIDANCE DIRECTORS AND LIBRARIANS MEETINGS**

Enclosure #4 has the yearly meetings for all secondary guidance directors and librarians. Please update your calendars with the dates pertinent to you.

Chris Hissong, ext. 1002

14. **PROFESSIONAL LEAVE FORMS**

A reminder to all staff that professional leave forms must be submitted ten (10) days in advance of the leave date.

Karyle Green, ext. 1001

15. **CLARIFICATIONS ON EACS TRAVEL POLICY**

EACS policy does not allow for reimbursed meals purchased for a one-day conference. This meets the IRS taxability standard. The travel guidelines received with conference approvals indicate this is not a reimbursable item. This policy change was enacted several years ago.

Reimbursable Meals are those consumed by the employee; at a typical restaurant or food establishment on conference days of multiple day conferences. Meals purchased before leaving or after returning home are not
reimbursed. Meals the night before conference are not reimbursed unless you are over 250 miles from home and/or air travel is involved. Food purchased at a package/grocery cannot be considered for reimbursement.

The maximum amount allowed, by policy, for reimbursement is $44.00. The reimbursement is based on actual costs, not a per diem amount.

Please take note of the policy allowances when submitting for reimbursements.

Lois Goeglein, ext. 1006

Remember the Slogan:

EAST ALLEN COUNTY SCHOOLS ~ ENHANCING THE EDUCATION!
Lilly Endowment is pleased to announce that the Teacher Creativity Fellowship Program will be offered again for 2013. This will be the 26th year the Endowment has offered this competitive program, continuing the Endowment’s commitment to helping Indiana become an even more rewarding setting for teachers and other education professionals.

Again this year, individuals who have worked as licensed teachers, principals and assistant principals in Indiana’s public, private and parochial schools since at least Fall 2010 are eligible to apply for the $10,000 grants. Former recipients of Teacher Creativity Fellowships who held one of these positions and who received their first grant before 2006 also may apply; later recipients are not eligible. An individual may receive up to two grants through this program during his or her lifetime.

The Teacher Creativity Fellowship Program will support up to 100 creative projects that are personally renewing and intellectually revitalizing to individual Indiana teachers and education professionals. Personal renewal and individual intellectual growth continue to be the primary goals of this program. Proposed projects may contribute to students’ engagement and learning. Applicants are encouraged to discuss that aspect in their applications.

The Endowment will grant up to 100 Teacher Creativity awards of $10,000 each. Proposals will be judged on the substance, clarity, originality and feasibility of the project. Imagination and creativity have been the strongest features of funded proposals. Preference will be given to proposals demonstrating that substantial thought has been given to this renewal opportunity. Proposals simply to develop new course outlines or lesson units typically do not reflect sufficient imagination, creativity, or thought to merit an award. Applicants may access the 2012 news release that lists the 2012 Teacher Creativity Fellowship recipients and their projects, as well as “Tips for Writing Successful Proposals,” elsewhere on this website. Applicants are encouraged to print out the personal information form from the Teacher Creativity page on the website to use as the first page of the proposal.

The Endowment believes that engaged teachers, principals and assistant principals help produce engaged students. Any expected benefits of a proposal to the educator and her or his students must be described in the project proposal.

The Endowment also encourages teams of eligible individuals to submit collaborative proposals. If a collaborative project is funded, each participant may receive a $10,000 fellowship.
APPLICATION PROCEDURE
PLEASE SUBMIT THREE COMPLETE COPIES OF YOUR PROPOSAL AND ALL ATTACHMENTS.

There is no formal application. All proposals should be prepared using a 12-point font or larger. They should be submitted online. (Group applicants should submit the group's proposal with a joint description of the project, budget and timeline. Personal information, future plans, letters of recommendation, licenses and affirmations are specific to each individual but must be included with a group proposal.)

1. Personal information
You are encouraged to use the personal information form that can be completed on and printed from the Teacher Creativity page of the website as the first page of your proposal. Please note that the form cannot be submitted online.

All applicants must complete part A. In addition to part A, teachers also must complete part B, and principals and assistant principals also must complete part C.

A. Legal name (as reported to the IRS)
   - Home address (street address or P.O. Box, city, state and ZIP)
   - Home telephone
   - Social Security Number
   - School email address (if available)
   - Personal email address (optional)
   - Date of birth (optional)
   - Employing school corporation (if applicable)
   - Employing school name
   - Employing school address and telephone number
   - Educational background
   - Length and nature of teaching experience

B. Teachers: Current teaching position and subject matter

C. Principals and assistant principals:
   - Length and nature of administrative experience
   - Current administrative position

The following items 2-5 should be covered in no more than three single-spaced pages.

2. Description of proposed project
Proposals should include sufficient detail to demonstrate that 1) the applicant is knowledgeable about the topic; 2) the applicant has the skills necessary to complete the project; and 3) the project is feasible (e.g., arrangements, locations, key contacts and so forth).

Each proposal must begin with a title, amount requested and a 50-word summary of the proposed project, then proceed to address the following:
- What is the rationale for your project, including specific project goals?
- What specific activities will you engage in to accomplish these goals?
- Describe how this project is creative for you. How will it be renewing?
- What do you expect to happen as a result of this creative renewal project?
- Teachers: What follow-up activities might you anticipate for school year 2013-2014?

3. Budget
You must submit a budget. Each grant will be made for precisely $10,000. The summer project is the primary focus of the grant; expenditures during the six weeks must constitute the bulk of the requested budget. The budget should reflect out-of-pocket expenses (transportation, lodging, supplies, mileage, taxes and so forth). After budgeting for out-of-pocket expenses, remaining funds may be designated as a personal stipend. Please note that because this grant in most cases will be subject to federal income tax, you are encouraged to include a line item to cover tax liability as needed.

4. Timeline
Teachers: Include a detailed, comprehensive, six-week summer schedule of activities (ending no later than August 31, 2013) and projected follow-up activities planned for school year 2013-2014.

Principals and assistant principals: Include a detailed schedule of activities that will be completed no later than August 31, 2014.

5. Statement of future plans
Teachers: Submit a statement affirming your present intention to teach in Indiana through school year 2013-2014.

Principals and assistant principals: Submit a statement affirming your present intention to remain in your role as principal or assistant principal in Indiana through school year 2014-2015.

6. Recommendation letter
Your proposal should include convincing evidence that you will be able to accomplish the project's goals. You must attach to your three-page proposal a signed letter of professional recommendation on official letterhead from a recognized authority or otherwise qualified person who can speak for your general ability and capacity to complete the proposed project. You may submit up to three recommendations. Reviewers spend considerable time on the letters of recommendation and view favorably letters that reflect the person's familiarity with you and your proposed project.

7. Indiana license
Teachers: Include a copy of your valid Indiana teaching license.

Principals and assistant principals: Include a copy of your valid Indiana administrative license.

8. Affirmation
Principals and assistant principals: Include a statement that affirms your district’s or governing board’s approval of your participation in the proposed project.

SELECTION AND PAYMENT PROCEDURE SCHEDULE
Please note the proposal deadline date. Without exception, applications must be postmarked by November 2, 2012.

An impartial panel will review proposals in January. The Endowment plans to notify recipients by February 22, 2013.

Payments are scheduled to be made after March 1, 2013. The Endowment will pay the $10,000 award directly to the fellowship recipient and will issue an IRS income reporting Form 1099 Misc. or other appropriate IRS report at the beginning of 2014.

APPLICATION SUBMISSION
Mail three complete copies of your proposal, including all attachments with all copies, to:

Barbara S. DeHart
Program Director, Education
Lilly Endowment Inc.
P.O. Box 88068
Indianapolis, Indiana 46208-0068
317/924-5471

A completed application must include one original and two copies (three sets total) of all required materials. All application materials become the property of the Endowment and will not be returned.
Be a part of the
Urban Run/Walk September 15, 2012
Just a $10.00 fee to participate Registration 9:30 to 10:00 a.m.

Support the Urban League
Call 260-745-3100 for more information
In our ongoing effort to assist you in maximizing your health care investment while offering your plan participants clinically appropriate prescription therapy, we are announcing changes to the CVS Caremark Prescribing Guide (PG, aka formulary) and Performance Drug List (PDL) effective October 1, 2012. The review process focused on many factors, including the following:

- Adding products that have demonstrated enhanced clinical efficacy and/or provide more convenient dosage forms;
- Removing products that may require less convenient therapy/dosage, have more side effects, or may cost more when compared to available options on the CVS Caremark drug list.

We anticipate that the overall impact to your members will be minimal and should result in few disruptions as a result of these changes. Most of changes are additions. Most of the deletions are due to generic availability. There are a few changes that will result in a change from tier 2 to tier 3: Bravelle (fertility), Byetta, Iressa (Specialty oncology), Metadate CD and Suboxone Film.

Plan participants who will experience these negative copay impacts will receive targeted advance written notifications of the changes to give them an opportunity to discuss therapeutic alternatives with their physicians as clinically appropriate.

Attached are copies of the change details reports and the October 2012 PDL.

Please encourage your plan participants to use the Caremark Web site, www.caremark.com, to view the most current version of the drug list, as well as to review their prescription drug benefit information, request mail service orders and research drug information.

We appreciate the opportunity to service your prescription benefit needs. If you have any questions regarding these changes, please do not hesitate to contact us.
This report highlights all changes (additions and deletions) to the CVS Caremark Prescribing Guide.

**ADDITIONS:**

<table>
<thead>
<tr>
<th>Product</th>
<th>Therapeutic Category/Subcategory</th>
<th>Indication</th>
<th>Alternatives/Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Atelvia</strong></td>
<td>Endocrine and Metabolic/Calcium Regulators/Bisphosphonates</td>
<td>Atelvia is indicated for the treatment of postmenopausal osteoporosis.</td>
<td>To provide an additional once-weekly treatment option for osteoporosis that does not need to be administered on an empty stomach.</td>
</tr>
<tr>
<td>(risedronate delayed-release)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Brilinta</strong></td>
<td>Hematologic/Platelet Aggregation Inhibitors</td>
<td>Brilinta is indicated to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) (unstable angina, non-ST elevation myocardial infarction [NSTEMI], or ST elevation myocardial infarction [STEMI]).</td>
<td>To provide an antiplatelet option that is superior to Plavix (clopidogrel) at reducing cardiovascular events in patients with ACS and is recommended by the American College of Cardiology Foundation and the American Heart Association for use in patients with unstable angina and NSTEMI.</td>
</tr>
<tr>
<td>(ticagrelor)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Edurant</strong></td>
<td>Anti-infectives/Antiretroviral Agents/Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)</td>
<td>Edurant, in combination with other antiretroviral agents, is indicated for the treatment of HIV-1 infection in treatment-naïve adult patients.</td>
<td>To provide an additional NNRTI option with a lower risk of dyslipidemia and neuropsychiatric adverse events.</td>
</tr>
<tr>
<td>(rilpivirine)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Product</td>
<td>Therapeutic Category/Subcategory</td>
<td>Indication</td>
<td>Alternatives/Comments</td>
</tr>
<tr>
<td>------------------</td>
<td>---------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| Fluoxetine 60 mg (fluoxetine) | Central Nervous System/ Antidepressants/ Selective Serotonin Reuptake Inhibitors (SSRIs) | Fluoxetine is indicated for the treatment of:  
• Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Bulimia Nervosa and Panic Disorder (with or without agoraphobia) in adults.  
• MDD in children and adolescents aged 8 to 18 years and OCD in children and adolescents aged 7 to 17 years. | To provide an additional formulation of fluoxetine that may be more convenient for patients requiring fluoxetine doses of greater than 40 mg/day. |
| Generic Agents: |                                  |                                                                             |--------------------------------------------------------------------------------------|
| Fluvastatin      | Cardiovascular/ Antilipemics/ HMG-CoA Reductase Inhibitors               | Fluvastatin is indicated for:  
• The treatment of both familial and nonfamilial hypercholesterolemia and mixed dyslipidemia.  
• The secondary prevention of cardiovascular disease. | To provide an additional generic statin option with a low potential for drug interactions. |
| Irbesartan       | Cardiovascular/ Angiotensin II Receptor Antagonists                      | Irbesartan is indicated for the treatment of:  
• Hypertension.  
• Diabetic nephropathy with an elevated serum creatinine and proteinuria (> 300 mg/day) in patients with type 2 diabetes and hypertension. | To provide an additional generic angiotensin II receptor blocker (ARB) option with an indication for diabetic kidney disease. |
### Prescribing Guide Change Detail Report
Effective 10-01-2012
*(Standard Drug List Reflects Exclusions)*

<table>
<thead>
<tr>
<th>Product</th>
<th>Therapeutic Category/Subcategory</th>
<th>Indication</th>
<th>Alternatives/Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>irbesartan/hydrochlorothiazide</td>
<td>Cardiovascular/Angiotensin II Receptor Antagonists/Diuretic Combinations</td>
<td>Irbesartan/hydrochlorothiazide is indicated for the treatment of hypertension.</td>
<td>To provide an additional generic ARB and diuretic combination therapy option.</td>
</tr>
</tbody>
</table>

**DELETIONS:**

<table>
<thead>
<tr>
<th>Product</th>
<th>Therapeutic Category/Subcategory</th>
<th>Indication</th>
<th>Alternatives/Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Iressa (gefitinib)</td>
<td>Antineoplastic Agents/Kinase Inhibitors</td>
<td>Iressa is indicated as monotherapy for the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies who are benefiting or have benefited from Iressa.</td>
<td>Iressa (gefitinib) has been withdrawn from the market by the manufacturer due to lack of efficacy at prolonging survival.</td>
</tr>
<tr>
<td>Product</td>
<td>Therapeutic Category/Subcategory</td>
<td>Indication</td>
<td>Alternatives/Comments</td>
</tr>
<tr>
<td>---------</td>
<td>---------------------------------</td>
<td>------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td><strong>Metadate CD</strong>&lt;br&gt;(methylphenidate extended-release)</td>
<td>Central Nervous System/Attention Deficit Hyperactivity Disorder</td>
<td>Metadate CD is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).</td>
<td>Availability of other stimulant options for the treatment of ADHD. Alternatives on the Prescribing Guide are amphetamine/dextroamphetamine mixed salts extended-release (Adderall XR), dexamphetamine (Focalin), dextroamphetamine (Dexedrine), dextroamphetamine extended-release (Dexedrine Spansule), methylphenidate (Methyl), methylphenidate (Ritalin), methylphenidate extended-release (Concerta), methylphenidate extended-release (Ritalin LA), methylphenidate extended-release 10 mg, Daytrana (methylphenidate transdermal), Focalin XR (dexamphetamine extended-release), Intuniv (guanfacine extended-release), Strattera (atomoxetine) and Vyvanse (lisdexamfetamine).</td>
</tr>
<tr>
<td><strong>Suboxone Film</strong>&lt;br&gt;(buprenorphine/naloxone)</td>
<td>Central Nervous System/Psychotherapeutic-Miscellaneous/Partial Narcotic Agonist/Narcotic Antagonist Combinations</td>
<td>Suboxone Film is indicated for the treatment of opioid dependence.</td>
<td>Availability of other opioid dependence therapy options. An alternative on the Prescribing Guide is naltrexone (ReVia).</td>
</tr>
</tbody>
</table>
This report highlights all changes (additions and deletions) to the CVS Caremark Performance Drug List.

**ADDITIONS:**

<table>
<thead>
<tr>
<th>Product</th>
<th>Therapeutic Category/Subcategory</th>
<th>Indication</th>
<th>Alternatives/Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Brand Agents:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aggrenox</td>
<td>Hematologic/Platelet Aggregation</td>
<td>Aggrenox is indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis.</td>
<td>To provide an additional antiplatelet option that reduces the risk of stroke without increasing the risk of bleeding complications compared with aspirin alone.</td>
</tr>
<tr>
<td>(dipyridamole extended-release/aspirin)</td>
<td>Inhibitors</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atelvia</td>
<td>Endocrine and Metabolic/Calcium</td>
<td>Atelvia is indicated for the treatment of postmenopausal osteoporosis.</td>
<td>To provide an additional once-weekly treatment option for osteoporosis that does not need to be administered on an empty stomach.</td>
</tr>
<tr>
<td>(risedronate delayed-release)</td>
<td>Regulators/Bisphosphonates</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brilinta</td>
<td>Hematologic/Platelet Aggregation</td>
<td>Brilinta is indicated to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) (unstable angina, non-ST elevation myocardial infarction [NSTEMI], or ST elevation myocardial infarction [STEMI]).</td>
<td>To provide an antiplatelet option that is superior to Plavix (clopidogrel) at reducing cardiovascular events in patients with ACS and is recommended by the American College of Cardiology Foundation and the American Heart Association for use in patients with unstable angina and NSTEMI.</td>
</tr>
<tr>
<td>(ticagrelor)</td>
<td>Inhibitors</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Product</td>
<td>Therapeutic Category/ Subcategory</td>
<td>Indication</td>
<td>Alternatives/Comments</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| Effient      | Hematologic/Platelet Aggregation Inhibitors | Effient is indicated for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with ACS who are to be managed with percutaneous intervention (PCI) as follows:  
• Patients with unstable angina or NSTEMI.  
• Patients with STEMI when managed with either primary or delayed PCI. | To provide an additional antiplatelet option that is superior to Plavix (clopidogrel) at reducing thromboembolic events in patients with ACS who receive scheduled stenting, and who are younger than 75 years of age and weigh at least 60 kg. |
| Fluoxetine 60 mg | Central Nervous System/Antidepressants/Selective Serotonin Reuptake Inhibitors (SSRIs) | Fluoxetine is indicated for the treatment of:  
• Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Bulimia Nervosa and Panic Disorder (with or without agoraphobia) in adults.  
• MDD in children and adolescents aged 8 to 18 years and OCD in children and adolescents aged 7 to 17 years. | To provide an additional formulation of fluoxetine that may be more convenient for patients requiring fluoxetine doses of greater than 40 mg/day.  
“FLUOXETINE 60 MG” will not be listed separately on the Performance Drug List, since “fluoxetine” is already listed. |
# Performance Drug List Change Detail Report
Effective 10-01-2012
*(Standard Drug List Reflects Exclusions)*

<table>
<thead>
<tr>
<th>Product</th>
<th>Therapeutic Category/ Subcategory</th>
<th>Indication</th>
<th>Alternatives/Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Generic Agents:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>clopidogrel</td>
<td>Hematologic/ Platelet Aggregation Inhibitors</td>
<td>Clopidogrel is indicated for: • ACS. • Recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease.</td>
<td>To provide a generic antiplatelet therapy option that is approved for multiple indications including recent stroke and peripheral arterial disease, that is associated with a lower bleeding risk than Effient (prasugrel) or Brilinta (ticagrelor), and that has the most long-term data.</td>
</tr>
<tr>
<td>fluvastatin</td>
<td>Cardiovascular/ Antilipemics/ HMG-CoA Reductase Inhibitors</td>
<td>Fluvastatin is indicated for: • The treatment of both familial and nonfamilial hypercholesterolemia and mixed dyslipidemia. • The secondary prevention of cardiovascular disease.</td>
<td>To provide an additional generic statin option with a low potential for drug interactions.</td>
</tr>
<tr>
<td>ibandronate</td>
<td>Endocrine and Metabolic/ Calcium Regulators/ Bisphosphonates</td>
<td>Ibandronate is indicated for the treatment and prevention of postmenopausal osteoporosis.</td>
<td>To provide a once-monthly generic therapy option for the treatment and prevention of osteoporosis.</td>
</tr>
<tr>
<td>irbesartan</td>
<td>Cardiovascular/ Angiotensin II Receptor Antagonists</td>
<td>Irbesartan is indicated for the treatment of: • Hypertension. • Diabetic nephropathy with an elevated serum creatinine and proteinuria (&gt; 300 mg/day) in patients with type 2 diabetes and hypertension.</td>
<td>To provide an additional generic angiotensin II receptor blocker (ARB) option with an indication for diabetic kidney disease.</td>
</tr>
</tbody>
</table>

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

©2012 Caremark, L.L.C. All rights reserved.
Performance Drug List Change Detail Report  
Effective 10-01-2012  
(Standard Drug List Reflects Exclusions)

<table>
<thead>
<tr>
<th>Product</th>
<th>Therapeutic Category/ Subcategory</th>
<th>Indication</th>
<th>Alternatives/Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>irbesartan/hydrochlorothiazide</td>
<td>Cardiovascular/ Angiotensin II Receptor Antagonists/ Diuretic Combinations</td>
<td>Irbesartan/hydrochlorothiazide is indicated for the treatment of hypertension.</td>
<td>To provide an additional generic ARB and diuretic combination therapy option.</td>
</tr>
</tbody>
</table>

**DELETIONS:**

<table>
<thead>
<tr>
<th>Product</th>
<th>Therapeutic Category/ Subcategory</th>
<th>Indication</th>
<th>Alternatives/Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boniva (ibandronate)</td>
<td>Endocrine and Metabolic/ Calcium Regulators/ Bisphosphonates</td>
<td>Boniva tablets are indicated for the treatment and prevention of postmenopausal osteoporosis.</td>
<td>The “A”-rated generic ibandronate will replace the branded agent Boniva (ibandronate) on the Performance Drug List.</td>
</tr>
<tr>
<td>Bravelle (urofollitropin)</td>
<td>Endocrine and Metabolic/ Fertility Regulators/ Ovulation Stimulants, Gonadotropins</td>
<td>Bravelle is indicated for ovulation induction in patients who have previously received pituitary suppression.</td>
<td>Availability of other gonadotropin therapy options. An alternative on the Performance Drug List is Follistim AQ (follitropin beta).</td>
</tr>
<tr>
<td>Byetta (exenatide)</td>
<td>Endocrine and Metabolic/ Antidiabetics/ Incretin Mimetic Agents</td>
<td>Byetta is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.</td>
<td>Availability of other incretin mimetics with superior efficacy that are administered less frequently. Alternatives on the Performance Drug List include Bydureon (exenatide extended-release) and Victoza (liraglutide).</td>
</tr>
</tbody>
</table>

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

©2012 Caremark, L.L.C. All rights reserved.
## Performance Drug List Change Detail Report
**Effective 10-01-2012**
*(Standard Drug List Reflects Exclusions)*

<table>
<thead>
<tr>
<th>Product</th>
<th>Therapeutic Category/Subcategory</th>
<th>Indication</th>
<th>Alternatives/Comments</th>
</tr>
</thead>
</table>
| Coumadin (warfarin) | Hematologic/Anticoagulants          | Coumadin is indicated for:  
  - Prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism.  
  - Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement.  
  - Reduction in the risk of death, recurrent MI, and thromboembolic events such as stroke or systemic embolization after MI. | Coumadin (warfarin) is being removed from the Performance Drug List due to the availability of an “A”-rated generic, warfarin. |
| Prometrium (progesterone, micronized) | Endocrine and Metabolic/Progestins, Oral | Prometrium is indicated for use in:  
  - The prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogen tablets.  
  - Secondary amenorrhea. | Prometrium (progesterone, micronized) is being removed from the Performance Drug List due to the availability of an “A”-rated generic, progesterone, micronized. |

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

©2012 Caremark, L.L.C. All rights reserved.

106-25956b 073012  Pg. 5 of 5
<table>
<thead>
<tr>
<th>Secondary Guidance Director meetings</th>
<th>Secondary Librarian meetings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuesdays at 1:00</td>
<td>Thursdays/Fridays at 1:00</td>
</tr>
<tr>
<td>Board Room</td>
<td>Room 208 at Park Hill</td>
</tr>
<tr>
<td>September 10**Monday</td>
<td>September 27</td>
</tr>
<tr>
<td>November 13</td>
<td>October 19**Friday w/Media Para’s</td>
</tr>
<tr>
<td>January 22</td>
<td>November 29</td>
</tr>
<tr>
<td>March 19</td>
<td>December 20</td>
</tr>
<tr>
<td>April 23</td>
<td>January 24</td>
</tr>
<tr>
<td></td>
<td>February 22**Friday</td>
</tr>
<tr>
<td></td>
<td>March 22**Friday w/Media Para’s</td>
</tr>
<tr>
<td></td>
<td>April 26**Friday</td>
</tr>
</tbody>
</table>

Guidance Directors and Librarians:
Please e-mail any agenda items to Chris Hissong to be included in the agenda’s.

The librarian meetings will include some type technology training for 60–90 minutes at each session.

If you have any questions, please send me an e-mail.
1. **SOWING SEEDS OF ENTREPRENEURSHIP AWARD**

Junior Achievement of Northern Indiana has won a 2012 MetLife Foundation Sowing the Seeds of Entrepreneurship Award. The award, one of only five across the nation, includes a $10,000 grant for developing and demonstrating the innovation. “Making It Relevant” is the title of Junior Achievement of Northern Indiana’s winning idea. This innovation focuses on locally modifying current JA middle school programs to include enhancements that will make the learning activities relevant to the challenging economic circumstances being experienced by young people and their families.

The funds will be used to support the initiative with maybe a small portion being left to support general operating.

**CONGRATULATIONS JUNIOR ACHIEVEMENT!**

2. **GOLD STAR COUNSELING PROGRAM AWARD**

Congratulations to **New Haven High School** Guidance department for receiving the 2012 Indiana Gold Star Counseling Award! Gold Star schools undergo a rigorous process to raise student achievement by creating local community advisory groups that review student data, set specific student goals, and commit to maximizing the time and skills of the school counselor. The official award presentation will be at the Indiana School Counselor Association (ISCA) fall conference in Indianapolis on November 2, 2012.

**WAY TO GO NEW HAVEN HIGH SCHOOL!**

3. **EACS NAMED TO PENNIES FOR PATIENTS® MILLIONAIRES CLUB**

Indiana students spent three weeks during the 2011-2012 school year contributing their spare change for Pennies for Patients. The fundraiser is designed to teach children the value of community service in a fun way. The Indiana Chapter named EACS to the Pennies for Patients Millionaires Club EACS raised a total of $10,900 to support and fund life-saving blood cancer research and patient services.

**CONGRATULATIONS EACS!**